Connective tissue growth factor (CTGF) is a secreted protein that regulates fibrosis. We hypothesized that CTGF is induced in a pressure-overloaded (PO) heart and that blocking the angiotensin II type 1 receptor would reduce CTGF expression. Accordingly, we administered olmesartan and compared its effects with other antihypertensive drugs in a PO heart. CTGF induction was determined in a rat PO model, and olmesartan, hydralazine or saline was continuously administered. The effects of olmesartan on CTGF induction, myocyte hypertrophy and fibrosis were evaluated. The effect of olmesartan on cardiac function was also examined in CTGF-and transforming growth factor-beta 1 (TGF-b1)-infused rats. CTGF was increased in the PO heart 3 days after aortic banding and was markedly distributed around the perivascular fibrotic area. After 28 days, blood pressure was not significantly different in the olmesartan and hydralazine groups, but olmesartan treatment reduced CTGF distribution in PO hearts. Olmesartan was associated with a significantly reduced myocyte hypertrophy index (4.77 ± 0.48 for olmesartan and 6.05 ± 1.45 for saline, Po0.01), fibrosis area (32.0 ± 15.5% compared with the saline group, Po0.05) and serum TGF-b1 level (62.6±10.6 ng ml À1 for olmesartan and 84.4±7.2 ng ml À1 for hydralazine, Po0.05). In addition, cardiac function was significantly preserved in the olmesartan group compared with the saline group. Finally, olmesartan ameliorated the cardiac dysfunction in CTGF-and TGF-b1-infused rats. Olmesartan attenuated CTGF induction, reduced perivascular fibrosis and ameliorated cardiac dysfunction in a PO heart. Our results provide insight into the beneficial effects of olmesartan on PO hearts, independent of blood-pressure lowering.
INTRODUCTION
Pressure overload (PO) causes myocyte hypertrophy, which leads to myocardial remodeling, including tissue fibrosis and subsequent heart failure. 1, 2 Connective tissue growth factor (CTGF) is a member of the CCN (cysteine-rich 61/chicken embryo fibroblast-10, CTGF/fibroblast-inducible secreted protein and nephroblastoma overexpressed) family of growth factors. [3] [4] [5] CTGF is a profibrotic factor implicated in tissue fibrosis, including heart failure, and it mediates the fibrotic signal by transforming growth factor beta (TGF-b) activation. [6] [7] [8] [9] CTGF is stimulated by various factors, including TGF-b and angiotensin II (Ang II). [10] [11] [12] Ang II has an important role in both myocyte hypertrophy and myocardial fibrosis induced by PO. 13 The inhibition of Ang II production and/or blockade of Ang II type 1 receptor have beneficial effects on the hypertensive heart, and are therefore widely used to treat patients in the clinical field. In this study, we examined the induction of CTGF expression in PO rat hearts and examined the effects of olmesartan, an Ang II type 1 receptor blocker (ARB), on CTGF mRNA induction and myocyte hypertrophy using a rat model. We then determined and compared the change in CTGF distribution, fibrosis and serum TGF-b1 levels in an ARB-treated rat model.
METHODS

Animals and experimental protocols
All protocols involving experimental animals followed the local institutional guidelines for animal care, which are comparable to those in the Guide for the Care and Use of Laboratory Animals published by the Institute for Laboratory Animal Research (National Institutes of Health Publication No. 85-23, revised 1996) . Male Sprague-Dawley rats (weighing 250-300 g) were anesthetized with sodium pentobarbital (50 mg kg À1 , i.p.), and pressure overload was induced by banding the abdominal aorta at the suprarenal level as described previously. 14, 15 Briefly, the abdominal aorta was constricted at the suprarenal level with 4-0 silk by ligation with a blunted 19-gauge needle, which was then pulled out. The right carotid artery was cannulated, and aortic pressure was measured using an
RNA isolation
Total RNA was extracted as previously described. 20, 21 After treatment, the total RNA of the cells was isolated using RNA STAT-60 reagent (TEL-TEST) and stored in aliquots at À80 1C. Total RNA (2 mg) was reverse-transcribed according to the manufacturer's protocol (Superscript II Amplification System for First Strand cDNA Synthesis; Invitrogen, Carlsbad, CA, USA). Contamination with genomic DNA was eliminated by DNase I treatment before cDNA synthesis, as previously described. 22 The cDNA was diluted by fivefold before PCR amplification.
Quantitative real-time reverse transcription PCR (RT-PCR) analysis
To examine changes in CTGF and TGF-b1 mRNA levels, samples were analyzed using quantitative real-time RT-PCR with the comparative threshold cycle (ÀDDCt) method as previously described. [23] [24] [25] Briefly, mRNA coding for CTGF, TGF-b1 and 18s rRNA was quantified using the LightCycler rapid thermal cycler system (Roche Diagnostics, Lewes, UK) according to the manufacturer's instructions. A typical protocol took approximately 45 min and included a 10-min denaturation step, followed by 40 cycles of denaturation at 95 1C for 10 s, annealing at 65 1C for 10 s and extension at 72 1C for 20 s.
The primers were as follows: rat CTGF (208 bp): 5¢-TGGACTGAACCGTATGATTG-3¢ (sense) 5¢-GCTGGCTGCATCAACTTT-3¢ (antisense) rat TGF-b1 (300 bp): 5¢-GCAACAACGCAATCTATGAC-3¢ (sense) 5¢-CCTGTATTCCGTCTCCTT-3¢ (antisense) rat 18s rRNA:5¢-CCGCAGCTAGGAATAATGGA-3¢ (sense) 5¢-GAGTCAAATTAAGCCGCAGG-3¢ (antisense). There was rarely significant primer dimer formation within the number of cycles required for quantification in a range of experimental samples. Each RT-PCR was repeated at least three times to verify reproducibility.
Immunohistochemistry
Immunohistochemistry of fresh frozen sections of the rat samples was performed as previously described. 17 Cryostat-frozen sections were cut to a 5-mm thickness, air-dried and fixed with acetone for 10 min. Sections were then incubated with 5% H 2 O 2 in methyl alcohol for 30 min, washed with phosphatebuffered saline for 5 min for three times and blocked with 1% bovine serum albumin for 60 min. Paraffin blocks were cut into 5-mm thick sections, deparaffinized in xylene, rehydrated and blocked with 5% skim milk for human sections. Sections were then incubated with goat polyclonal anti-CTGF antibody (1:25; SC14939; Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4 1C in a humid atmosphere and stained with a labeled highpolymer staining kit (Histofine Simple Stain rat MAX PO (G) kit; Nichirei, Tokyo, Japan) combined with a diaminobenzidine tetrahydrochloride or 3-Amino-9-ethylcarbazole (AEC) kit (Dako, Carpinteria, CA, USA) according to the manufacturer's instructions.
Cardiac hypertrophy and fibrosis
Heart sections were stained with hematoxylin and eosin, Azan and Picrosirius red 26 to examine the extent of fibrosis. Sirius red (Direct Red 80; Sigma, St Louis, MO, USA) was dissolved in saturated picric acid solution (0.1%) to prepare the staining solution. The samples were examined with a BX50 microscope (Olympus, Tokyo, Japan) equipped with an AxioVision system (CarlZeiss, Germany) using normal light, as previously reported. 27 Cell width was measured at the nuclear level in longitudinally oriented cardiomyocytes using dedicated software (Image Proplus). 28 Fibrotic areas in a given photomicrograph were determined with Win Roof image analysis software (Mitani Corporation, Fukui, Japan).
Enzyme-linked immunosorbent assay (ELISA)
Blood samples were drawn from each rat and serum was collected by microcentrifugation and stored in aliquots at À30 1C until assayed by ELISA for TGF-b1 (R&D Systems). ELISA was performed as described in previous studies. [29] [30] [31] Briefly, a monoclonal antibody to rat TGF-b1 was used for capture, and a biotinylated polyclonal antibody was used for detection. Recombinant TGF-b1 protein served as a standard. The lower limit of sensitivity was 31.2 pg ml À1 , and the intra-and inter-assay coefficients of variation were o3 and o10%, respectively.
Statistical analysis
All values are given as the mean±s.d. Between-group variations were assessed using the two-tailed unpaired t-test. For multiple comparisons, analysis of variance was performed, and post-hoc analysis with Bonferroni's test was employed. P-values o0.05 were considered significant.
RESULTS
CTGF was induced in pressure-overloaded hearts
We first examined CTGF expression in the PO hearts in rats. Real-time quantitative RT-PCR analysis demonstrated that CTGF mRNA expression was significantly induced after 3 days of aortic banding ( Figure 1a ). Interestingly, CTGF production was observed in the PO heart and ascending aorta but not in the infrarenal descending aorta (data not shown), indicating that this induction was not due to systemic hormonal factors. TGF-b1 mRNA gradually increased in the PO heart and significantly increased 7 days after aortic banding (Figure 1b) . At the protein level, CTGF was distributed in the perivascular fibrosis area in the PO heart 3 days after banding, and CTGF-positive signals were observed in both the perivascular fibrotic area and the intracellular fibrotic area after 7 days of banding ( Figure 1c ).
Effect of olmesartan on cardiac hypertrophy in the pressure-overloaded heart We then treated PO rats with antihypertensive drugs and examined the effect on cardiac hypertrophy. Olmesartan was used and compared with hydralazine-and saline-administered groups (n¼6 in each group). As shown in Table 1 , there was a significant increase in systolic blood pressure in the saline-administered group. However, blood pressure was significantly ameliorated in rats treated with olmesartan in comparison with the saline-treated group (109 ± 10 and 135 ± 5 mm Hg; Po0.01) after 28 days of banding. The left ventricular hypertrophy in the olmesartan-treated group after 28 days of banding, as determined by echocardiography (that is, end-diastolic interventricular septal thickness) was significantly reduced as compared with the saline-treated group (1.22±0.08 and 1.57±0.08 mm; Po0.01). On the other hand, when rats were treated with hydralazine, systolic blood pressure decreased to levels similar to those in the olmesartan group, but end-diastolic interventricular septal thickness was increased (1.70±0.14 mm). The myocyte hypertrophy index was significantly worse in the hydralazine group than that in the olmesartan-treated group (5.60 ± 1.20 and 4.77 ± 0.48, Po0.05), indicating that the hypertrophic change in the PO heart was blood pressure independent.
Effect of olmesartan on CTGF expression, cardiac fibrosis and function in the PO heart We next examined CTGF expression and the extent of fibrosis in PO rats in the saline-and olmesartan-treated groups. In saline-treated rats, CTGF was observed around vascular smooth muscle cell (VSMC) layers in the PO heart after 7 days of aortic banding (data not shown). In contrast, there was no significant positive signal for CTGF in the olmesartan-treated heart (data not shown). At 28 days post-aortic banding, considerable CTGF distribution around the VSMC layers in the PO heart was observed in saline-treated rats (Figures 2a and d) , in contrast with moderate CTGF expression around the VSMC layers in the hydralazine-treated heart (Figures 2b and e) . The olmesartantreated heart showed clear signals of CTGF around the VSMC layers (Figures 2c and f) . Cardiac hypertrophic change was significantly attenuated in the olmesartan group compared with the blood pressure-matched hydralazine group after 28 days of banding ( Table 1) . The extent of fibrosis in the PO heart was quantitatively analyzed using Masson's trichrome staining. The fibrotic area was significantly reduced in the olmesartan-treated group compared with the salinetreated group (Figures 3a-g ). We then examined the serum TGF-b1 levels in olmesartan-treated PO hearts and compared them with the hydralazine-treated PO hearts (n¼6 olmesartan and n¼3 hydralazine). As shown in Figure 4 , serum TGF-b1 levels were significantly decreased in the olmesartan-treated group compared with the hydralazine-treated group (Po0.05). Next, we examined the ejection fraction of the PO hearts in each group. As shown in Figure 5a , the ejection fraction in the sham-operated group was 88.4±2.6%, and the ejection fraction in the olmesartan group was significantly preserved compared with the saline group.
Effect of olmesartan on cardiac function in the CTGF-and TGF-b1-infused heart
Finally, we examined the cardioprotective effect of olmesartan in CTGF-and TGF-b1-infused hearts. After 14 days of continuous administration of growth factors, cardiac function was reduced, and olmesartan ameliorated this cardiac dysfunction (Figure 5b ).
DISCUSSION
This study demonstrated that CTGF expression and fibrotic change were induced in the PO heart, and these effects were ameliorated by olmesartan treatment. The method we followed for our PO model is well established, and the blood pressure data in our model are consistent with previous reports, 15, 32, 33 indicating that our procedures are valid. When the aorta is constricted and PO is induced, one of the early events is an adaptive change of the vessels in the PO heart, referred to as perivascular fibrosis. In this study, we focused on perivascular change because this adaptive change results in consecutive pathological cardiac hypertrophy and heart failure from PO. 34 Perivascular fibrosis is mediated by several factors, including neurohumoral factors and mechanical stress on the vessel wall. Macrophages, fibroblasts and VSMCs have roles in this process. In the PO heart, VSMCs proliferated and produced profibrotic molecules, such as TGF-b1 and CTGF. VSMC proliferation is regulated by an AT 1 receptor-dependent mechanism in the PO heart, following an Ang II infusion model. 35 Tokuda et al. 36 reported that aortic constriction-induced PO enhanced angiotensin-converting enzyme activity after 1 day, peaked at 3 days and then fell, but to levels significantly higher than the basal level, by 14 days. Kai et al. 15 reported that PO-induced oxidative stress and perivascular fibrosis were attenuated by candesartan. Our findings that olmesartan attenuated CTGF induction and perivascular fibrosis in PO hearts are in line with these reports. These data suggest that ARB is likely to be beneficial in blocking early changes (that is, perivascular fibrotic response) in the PO heart.
We compared the effects of olmesartan with hydralazine in this study because hydralazine has been widely used as a blood pressurematched control in animal models. 37 ARB is widely used as an antihypertensive drug, and losartan and telmisartan have been reported to ameliorate interstitial and perivascular fibrosis; however, left ventricular hypertrophy was only partially preserved in the saltinduced hypertension model. 38 In this study, we examined the effect(s) of olmesartan, while controlling blood pressure and compared it with blood pressure-matched rats treated with another antihypertensive drug, hydralazine. Although the decrease in blood pressure was similar in the olmesartan-and hydralazine-treated groups, there were significant differences in cardiac hypertrophy and perivascular fibrosis between the two groups. Therefore, the inhibition of CTGF and perivascular fibrosis by olmesartan is an independent blood pressure-lowering mechanism.
Left ventricular PO resulting from hypertension activates a wide range of signaling pathways. In addition to loading conditions, Figure 2 Effect of antihypertensive drugs on CTGF distribution in rat PO hearts. (a) Saline was administered to the PO heart for 28 days, using an osmotic pump. Considerable distribution of CTGF-positive signals (red) was observed around the perivascular area and interstitial fibrotic area. The dotted boxed area shows the area that was observed at higher magnification in (d). (b) Hydralazine was administered to the PO heart for 28 days, using an osmotic pump. CTGF-positive signals (red) were observed around the perivascular area and interstitial space. The dotted boxed area shows the area observed at higher magnification in (e). (c) Olmesartan was administered to the PO heart for 28 days, using an osmotic pump. CTGF-positive signals (red) were faint around the perivascular area and interstitial space. The dotted boxed area shows the area observed at higher magnification in (f). it appears that the local release of neuroendocrine ligands can modulate myocyte hypertrophy and function along with extracellular matrix reorganization. 39 It has been shown that Ang II can activate the Smad pathway, which has a role in the regulation of CTGF associated with mitogen-activated protein kinase signaling. 10 Another group reported that SB203580, a p38 mitogen-activated protein kinase inhibitor, diminished Ang II-induced Smad2 phosphorylation. 40 Xia et al. 41 reported activation of the Smad signaling pathway after aortic constriction in a transverse aortic constriction model and Gao et al. 42 reported activation of the Smad signaling pathway in the Ang IIinfused heart. These data suggest that the Smad pathway might be associated with CTGF induction in the PO heart. CTGF development in a failing heart is a general response to evolving heart failure. Koitabashi et al. 43 reported that plasma CTGF levels were elevated in patients with heart failure. In the myocardial infarction model, CTGF induction was observed, and losartan prevented the induction of myocardial CTGF mRNA in rats after myocardial infarction and attenuated ventricular hypertrophy. 12 In the streptozocine diabetic heart, candesartan treatment has been Figure 3 Effect of antihypertensive drug on fibrotic change in rat PO hearts. Azan staining was performed to identify fibrotic change (blue). (a) Saline was administered to the PO heart for 28 days using an osmotic pump. Perivascular and interstitial fibrotic areas are shown (blue). The dotted boxed area shows the area observed at higher magnification in (d). (b) Hydralazine was administered to the PO heart for 28 days using an osmotic pump. Fibrosis (blue) was observed around the perivascular area and interstitial space. The dotted boxed area shows the area observed at higher magnification in (e). (c) Olmesartan was administered to the PO heart for 28 days using an osmotic pump. Fibrotic change (blue) was faint around the perivascular area and interstitial space. The boxed area in dots shows the area observed at higher magnification in (f). Quantification of the fibrotic area in PO hearts. The result of Azan staining (blue color) of PO hearts (28 days, n¼6 in each group) was quantified in each group using image analysis software. The fibrotic areas in the saline-treated PO hearts were considered to be 100, and the relative fibrotic areas in each group are shown (S, saline; H, hydralazine; O, olmesartan). Note that the olmesartan group showed a significant reduction of the fibrotic area compared with the saline-treated group. Figure 4 Serum TGF-b1 levels in the PO heart. Serum was collected 28 days after aortic constriction, and TGF-b1 level was determined by ELISA in the hydralazine and olmesartan groups (S, saline; H, hydralazine; O, olmesartan).
reported to ameliorate CTGF expression and ventricular remodeling. 44 Duisters et al. 45 reported that CTGF is regulated by two major cardiac microRNAs, which were downregulated in several models of cardiac hypertrophy and heart failure. Recently, Panek et al. 46 reported that cardiomyocyte-specific CTGF transgenic mice developed cardiac dysfunction but did not develop cardiac fibrosis. These reports support the significant role of CTGF in heart failure. Our results demonstrate that olmesartan attenuated CTGF induction in the PO heart and ameliorated both cardiac hypertrophy and perivascular fibrosis compared with blood pressure-matched controls. The discrepancy in fibrosis may be explained by different experimental methods. In our experimental model, the major source of CTGF was cardiac VSMC, not myocytes, and fibrosis was mainly perivascular. Therefore, the sizable role of VSMCs and perivascular fibrosis in the PO heart may have been modulated by olmesartan in this study. Because the beneficial effects of angiotensin-converting enzyme/ARB in heart failure are recognized, the cardioprotective effects of olmesartan may be because of its targeting of CTGF, an important factor in Ang IIinduced myocardial remodeling.
Our study demonstrated a reduction in serum TGF-b1 levels in the PO heart with ARB treatment compared with the hydralazine-treated group. As previously shown in other diseases, serum or plasma TGFb1 levels may be a biomarker for wound healing and fibrosis. [47] [48] [49] El-Agroudy et al. 50 reported that losartan significantly decreased plasma TGF-b1 levels in hypertensive renal transplant patients. Although careful observation of TGF-b1 levels in a larger number of samples is needed, TGF-b1 measurement may be useful for monitoring developing heart failure.
There are several limitations to this study. First, the attenuation of CTGF induction may be attributed to the attenuation of cardiac hypertrophy and fibrosis. Because olmesartan has antihypertrophic and antifibrotic effects, the CTGF attenuation may be a secondary result of reducing hypertrophy and/or fibrosis. However, rosiglitazone has been to shown to attenuate CTGF expression in the Ang IIstimulated SMC in vitro. 42 In addition, olmesartan showed a cardioprotective effect in a CTGF-and TGF-b1-infusion rat model. Given these data, we conclude that CTGF is likely to be one of the targets of olmesartan. Second, TGF-b (that is, TGF-b1, TGF-b2 and TGF-b3) activation as a consequence of CTGF induction was not confirmed. We did not primarily deal with the cascade of CTGF and TGF-b activation but focused on the effect of olmesartan on the PO heart by comparing blood pressure-matched controls. The signaling cascade of TGF-b activation, including the phosphorylation of Smad2/3, has been well characterized. Although we did not examine TGF-b activation in the PO heart, a previous study demonstrated late induction of TGF-b1 in the PO heart, 41 and our real-time RT-PCR results confirmed these data. In addition, serum TGF-b1 levels were better attenuated by olmesartan than hydralazine in our model (data not shown), suggesting that olmesartan treatment reduced TGF-b induction in our rat model.
In conclusion, we demonstrate olmesartan's protective effect on the PO heart by CTGF attenuation, showing that its ameliorative effects on cardiac dysfunction go beyond than lowering the blood pressure. Figure 5 (a) Effect of olmesartan on cardiac function in the PO heart. The ejection fraction was measured in the sham-operated and PO hearts (n¼6 in each group) after 28 days of aortic constriction (sham, sham heart; S, saline; H, hydralazine; O, olmesartan). Note that systolic function was preserved in the olmesartan group after 28 days of constriction, in contrast to the saline-and hydralazine-treated hearts. (b) Effect of olmesartan on cardiac function in the CTGF-and TGF-b1-infused hearts. After 14 days of continuous administration of growth factors, cardiac function was reduced in the nontreated rats (control), and olmesartan treatment (olmesartan) ameliorated this cardiac dysfunction.
